Tumor Mutational Load: A Novel Predictor for Clinical Benefit of Pembrolizumab-Reference-Cited by-同舟云学术

Tumor Mutational Load: A Novel Predictor for Clinical Benefit of Pembrolizumab

Published:2024-07-08 Issue:17 Volume:30 Page:3652-3654
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:

Author:

Hsu Fang-Chi¹^ORCID,Yen Yun²³^ORCID

Affiliation:

1. Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts. 1

2. Ph.D. Program in Graduate Institute of Cancer Biology and Drug Discovery, Taipei Medical University, Taipei, Taiwan. 2

3. Sino-American Cancer Foundation, Covina, California. 3

Abstract

Summary A recent study evaluated the efficacy of pembrolizumab across various cancers, classified according to tumor mutational load (TML) defined by whole-genome sequencing. Tumors exhibiting intermediate to high TML showed improved clinical benefit from pembrolizumab. This proof-of-concept study highlights clinical value of TML in patient selection, advancing precision immunotherapy and treatment strategies. See related article by Geurts et al., p. 3735

Publisher

American Association for Cancer Research (AACR)

Link

https://aacrjournals.org/clincancerres/article-pdf/doi/10.1158/1078-0432.CCR-24-1261/3472469/ccr-24-1261.pdf

Reference11 articles.

1. Efficacy of pembrolizumab and biomarker analysis in patients with WGS-based intermediate to high tumor mutational load: results from the Drug Rediscovery Protocol;Geurts;Clin Cancer Res,2024

2. The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs;van der Velden;Nature,2019

3. Comprehensive analyses of PBRM1 in multiple cancer types and its association with clinical response to immunotherapy and immune infiltrates;Yang;Ann Transl Med,2021

4. Targeting neoantigens to augment antitumour immunity;Yarchoan;Nat Rev Cancer,2017

5. Cancer neoantigens and applications for immunotherapy;Desrichard;Clin Cancer Res,2016